key: cord-0754972-wv9rt7ir
authors: Shi, Si; Liu, Xiaohui; Xiao, Jinling; Wang, Hongwei; Chen, Liyan; Li, Jianing; Han, Kaiyu
title: Prediction of adverse clinical outcomes in patients with coronavirus disease 2019
date: 2020-09-28
journal: J Clin Lab Anal
DOI: 10.1002/jcla.23598
sha: 28c24e1fc166dee4d209f996aa644f199da8163b
doc_id: 754972
cord_uid: wv9rt7ir

OBJECTIVE: This study aims to investigate blood and biochemical laboratory findings in patients with coronavirus disease (COVID‐19) and analyze the potential predictors of poor outcome in patients with COVID‐19. METHODS: The clinical, laboratory, and outcome data of 87 patients with COVID‐19 were collected and retrospectively analyzed. Only data collected at the time of admission were used in the analysis for predictors of poor outcome. These patients were divided into two groups: the adverse prognosis group (36 patients) and the non‐adverse prognosis group (51 patients). The adverse prognosis of COVID‐19 patients was defined as admission to the intensive care unit or death. RESULTS: On the univariate analysis, age, white blood cell (WBC) count, neutrophil counts, lymphocytes count, neutrophils‐to‐lymphocytes ratio (NLR), interleukin‐6, albumin‐to‐globulin ratio (AGR), albumin, lactate dehydrogenase, glutamyl transpeptidase, and blood glucose were found to be the significant predictors. On the multivariate analysis, the predictors of poor outcome of patients with COVID‐19 were NLR (OR = 2.741, [95% CI = 1.02 ~ 7.35], P = .045) and IL‐6 (OR = 1.405, [95% CI = 1.04 ~ 1.89, P = .025]). The receiver operating characteristic (ROC) curve revealed that the AUC of NLR, interleukin‐6, pneumonia severity index (PSI) score, and Confusion‐Urea‐Respiratory Rate‐Blood pressure‐65 (CURB‐65) score were 0.883, 0.852, 0.824, and 0.782, respectively. CONCLUSION: High interleukin‐6 (6 pg/mL, cuff value) and NLR (4.48, cuff value) can be used to predict poor outcomes in patients with COVID‐19 on admission, thus can serve as a beneficial tool for timely identifying COVID‐19 patients prone to poor outcome and reduce patient mortality through early intervention.

Severe acute respiratory syndrome coronavirus (SARS-CoV-2), which belongs to a unique clade of the sarbecovirus subgenus of the Orthocoronavirinae subfamily, was identified as the pathogen of coronavirus disease-2019 (COVID- 19) in January 2020. 1 As of the end of August 30, 2020, there were 24 854 140 cases reported, with 838 924 deaths (3.3%) worldwide. Severe and critical patients with COVID-19 present high mortality rate, and occurrence of acute respiratory distress syndrome (ARDS) or multi-organ dysfunction (MODS) significantly increasing its mortality risk. 2 It has been reported that the rate of ARDS in severe patients with COVID-19 was 15.9 to 29%. 1 The more critical the condition of the infected individual, the greater the chances of complications from SARS and multiple organ failure, or even death.

Previous studies have shown that many laboratory biomarkers, such as lymphocyte count, interleukin-6 (IL-6), ratio of albumin to globulin (AGR), neutrophil count, hypersensitivity, C-reactive protein (CRP), creatine kinase, blood urea, thrombocytopenia, lactate dehydrogenase (LDH), and D-dimer, are out of normal ranges in patients with COVID-19. [3] [4] [5] These laboratory biomarkers are routine and are the most available in clinics. However, available markers for predicting the progression of patients with COVID-19 are limited. Reverse transcription-polymerase chain reaction (RT-PCR) is one of the golden standards in the clinical diagnosis of COVID-19. 6 Nevertheless, blood and biochemical laboratory findings could also be used for early detection, prognosis, and prediction of disease progression. Thus, there is a need to look for indicators to predict the severity of COVID-19 and its adverse clinical outcomes.

The present study aimed to determine whether the blood and biochemical indexes could differentiate between COVID-19infected patients with or without adverse prognosis. The investigators attempted to establish an early risk factor stratification based on adverse prognostic factors, in order to reduce patient mortality and alleviate the shortage of medical resources.

The present study was approved by the Medical Ethics Committee 

Patients with COVID-19 were divided into adverse prognosis group and non-adverse prognosis group. Each patient with COVID-19 was followed up for at least one month. An adverse prognosis was considered as the admission to the intensive care unit (ICU) or death.

The criterion for admission to the ICU was either (a) respiratory failure occurrence that requires mechanical ventilation; (b) shock occurrence; or (c) combined with other organ failure requiring ICU monitoring and treatment. 4 The independent prognosis predictors were determined by comparing the clinical and applied biochemical indexes between the adverse prognosis group and non-adverse prognosis group. Pneumonia severity index (PSI) and Confusion-Urea-Respiratory Rate-Blood pressure-65 (CURB-65) (defined as an Abbreviated Mental Test Score of 8 or less, blood urea nitrogen level >7 mmol/L [19 mg/dL], respiratory rate of ≥30 breaths/min, systolic blood pressure <90 mm Hg, diastolic blood pressure ≤60 mm Hg, age ≥65 years older]) were used to assess severity indices of COVID-19.

In this article, we attempt to combine the PSI and CURB-65 scores to predict the severity of patients with COVID-19 and its adverse clinical outcomes.

The age and days were presented in median (range), and the classification variables were presented in number (%). Furthermore, normally distributed measurement data were presented as Mean ± standard deviation (SD), the comparison of two sample means was performed by t test, and the comparison of more than two sample means was performed using the variance test. Non-normally distributed measurement data were presented in median [interquartile range (IQR)]

and analyzed by Mann-Whitney test. The measurement data were analyzed by chi-square or Fisher's accurate test, and the logistic re- 20.7%), respiratory disease (n = 10; 11.4%), and malignant tumor (n = 2; 2.3%) ( Table 1 ). At the time of admission, most patients had fever, cough and fatigue, and one-third of these patients had difficulty in breathing. The other symptoms included muscle soreness, headache, nasal congestion, runny nose, sore throat, and diarrhea.

The median time from admission to severe pneumonia in the poor outcome group was 5.5 days, with a minimum of one day and a maximum of 14 days.

Among the 87 confirmed patients, the lymphocyte count decreased in 36 cases (41.3%), but there was no significant change in hemoglobin count and platelet count. (Table 2 ) Other biochemical abnormalities seen in the patients were elevated serum LDH levels (n = 31; 35.6%), increased glutamyl transpeptidase levels (n = 23;

26.4%), decreased albumin levels (n = 39; 44.8%), decreased AGR (n = 77; 88.5%), increased blood glucose levels (n = 37; 42.5%), increased blood calcium (n = 45; 51.7%), and increased IL-6 levels (n = 47; 54.0%). Patients with COVID-19 in the adverse prognosis group had lower lymphocyte counts than patients with COVID-19

in the non-adverse prognosis group (P < .001), lower albumin levels (P < .001), a reversal of the AGR (P < .001), higher white blood cell (WBC) count, (P = .049), higher neutrophils count (P < .001), higher NLR (P < .001), higher glutamyl transpeptidase levels (P = .004), higher LDH levels (P < .001), higher IL-6 levels (P < .001), and higher blood glucose levels (P = .003). Other laboratory measures did not differ significantly between the two groups.

The average age of the nine patients who died was 65 years old (range: 56-74 years old). Among these patients, seven patients (77.7%) had a basic medical history, three patients (33.3%) had a diabetes history, and four patients (44.4%) had hypertension. In addition, in COVID-19 dead patients, CRP and AGR were increased in all nine cases (100%). Furthermore, a decrease in albumin levels (n = 8;

88.9%), lymphocyte count (n = 7; 77.7%) and increase in NLR, IL-6, blood glucose, and LDH (n = 7; 77.8%) was observed. The imaging changes, which were mainly ground-glass opacity (GGO) shadows and consolidation, were observed in all dead patients. The X-ray or computed tomography (CT) revealed that 44 patients (50.6%) had multiple or bilateral lung lobes. The most common CT manifestations were GGOs, crazy paving-like changes (GGO with interlobular septal and interlobular septal thickening), and consolidation, without mediastinal lymph node lesions. This mainly occurred in the subpleural part of the lower lobe.

The numbers for age (P = .001), white blood cell (WBC) count (P = .049), neutrophils count (P = .001), and lymphocyte count (P = .001), and the NLR (P = .001), IL-6 (P = .001), LDH (P = .001), blood glucose (P = .003), glutamyl transpeptidase (P = .004), AGR .049

Increased 10 (11.5%)

.041

Decreased 10 (11.5%) 6 (11.8)

Neutrophil count (18- TA B L E 2 (Continued) (P = .001), and albumin (P = .001) levels in the single-factor analysis were correlated with the poor outcome of the disease (P < .01) ( 

Receiver operating characteristic curve analysis suggested that various parameters could be used to assist the prediction of poor outcome of patients with COVID-19, with areas under the curve of 0.883 for NLR, 0.852 for IL-6, 0.782 for PSI and 0.695 for CURB-65.

( The neutrophil-to-lymphocyte ratio (NLR) integrates information on both the innate and adaptive compartments of the immunity and represents a reliable measure of the inflammatory burden. 10 The NLR has been proposed as an easy parameter to assess the individual inflammatory status. 11 It has proven its accuracy in predicting the outcome of patients with major cardiac events, 12 ischemic stroke, 13 cancers, 14 sepsis, and infectious pathologies. 15 It can be used as a reliable and simple index to determine the increase in inflammation in chronic obstructive pulmonary diseases patients. 16 It is a common index to evaluate the severity of bacterial infection and prognosis of patients with pneumonia and tumors. 17 In this study, we found that the neutrophil count in most patients (84.00%) was within the normal range, but poor outcome patients with COVID-19 had a continuous increase in neutrophils. This is because respiratory viruses can suppress the innate immune response and evade the host's innate immunity, while neutrophils are the main natural immune cells that regulate the innate immune response against viral lung infections. 18 Our study explored the relationship between NLR and COVID-19

and found that patients with NLR >4.48 were more likely to develop poor prognosis of patients with COVID-19.

A previous study reported that out of 1099 COVID-19-infected cases, 83.2% had lymphocytopenia. 19 The CD3+/CD4+/CD8+/ CD19+ T cell counts are reported to decline significantly in the early SARS-CoV infection period. 20 The virus molecules transmit across respiratory mucosa to infect more cells, which thus results in the cytokine storm, produces various immune reactions, and leads to alterations of WBC count and immunocytes including lymphocytes in the peripheral blood. 21 It was found that the continuous decrease in lymphocyte count was correlated to the progress and prognosis of patients with COVID-19, and the lymphocyte-related indexes may be a potential predictor. 22 score was not creditable enough to predict the mortality of virus pneumonia. 32 After NLR or IL-6 was incorporated into PSI and CURB-65 models respectively, it was found that the prediction effect of the improved model was significantly better than that of the original model. The AUC of a combination of the IL-6 level, NLR, and PSI score was 0.973. The combined prediction value of these three parameters is better than that of a single factor, and it is of great The present study has several limitations. The sample size (87 samples) was relatively small. Further studies with a larger sample size are needed to confirm these results. Furthermore, the investigators intend to further improve the study in the future.

Heilongjiang province [NO. H2018019]. We are grateful to all the patients and individuals in the study who made this work possible.

We would also like to thank the investigators who contributed to data collection for this study and their support and care of patients.

The present study was approved by the Medical Ethics Committee of Tongji Affiliated Hospital of Huazhong University of Science and

Technology and conforms to the principles of Helsinki declaration.

Jinling Xiao https://orcid.org/0000-0002-8891-5293

A novel coronavirus from patients with pneumonia in China

Analysis of clinical features and outcomes of 161 patients with severe and critical COVID-19: a multicenter descriptive study

Clinical Characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. medRxiv

Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer

Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19)

Correction to: clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center For Disease Control And Prevention

Neutrophil-to-Lymphocyte Ratio in acute cerebral hemorrhage: a system review

Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill

Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome

Neutrophil to lymphocyte ratio predicts poor prognosis in ischemic cerebrovascular disease

Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis

Lymphocytopenia and neutrophil-lymphocyte count ratio predict bacteremia better than conventional infection markers in an emergency care unit

The importance of Neutrophilto-Lymphocyte Ratio in chronic obstructive pulmonary disease

Neutrophil to lymphocyte ratio and the extent of Coronary Artery disease: results from a large cohort study

Clinical features and treatment of 2019-nCov pneumonia patients in Wuhan: report of a couple of cases

Clinical characteristics of coronavirus disease 2019 in China

Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage

Interleukin-6 as a potential biomarker of COVID-19 progression

Transgenic blockade of interleukin 6 transsignaling abrogates inflammation

IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer

Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies

Serum albumin level as a potential marker for deciding chemotherapy or best supportive care in elderly, advanced non-small cell lung cancer patients with poor performance status

Serum albumin as a significant prognostic factor for patients with gastric carcinoma

ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection

Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy

A major outbreak of severe acute respiratory syndrome in Hong Kong

Clinical features predicting mortality risk in patients with vral pneumonia: The MuLBSTA Score

Prediction of adverse clinical outcomes in patients with coronavirus disease 2019